Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes

Diabetes & Metabolism
Michel MarreP Fontaine

Abstract

PREDICTIVE (an ongoing multinational observational study) provides an opportunity to explore the impact of insulin detemir use in routine clinical practice. Here, we report on long-term (52-week) data from a French cohort of patients (n=1772), comprising 643 with type 1 diabetes and 1129 with type 2 diabetes. Patients were prescribed insulin detemir at their physician's discretion and assessed at various visits (baseline, 12 weeks, 26 weeks and 52 weeks). The primary endpoint was the frequency of serious adverse drug reactions, including major hypoglycaemia. Secondary endpoints included minor and nocturnal hypoglycaemia, glycaemic control (HbA(1c), fasting blood glucose and variability of fasting blood glucose) and weight change. The incidence of serious adverse drug reactions was low throughout the study, seen in 10 patients with type 1 diabetes (14 events, 1.6%) and seven with type 2 diabetes (seven events, 0.6%). In both type 1 and type 2 diabetes cohorts, the overall minor and nocturnal hypoglycaemic events were reduced from baseline (P<0.001), with no clinically significant changes in weight from baseline to endpoint. After 52 weeks of treatment with insulin detemir, glycaemic control improved, with reductions in: HbA(1c),...Continue Reading

References

Apr 24, 2001·Diabetes Care·H Yki-Järvinen
Aug 14, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·M Korytkowski
Apr 28, 2004·Diabetes Care·Philip HomeUNKNOWN Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group
Nov 10, 2004·Diabetes Research and Clinical Practice·K RaslováN Hâncu
Feb 5, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Therese M Chapman, Caroline M Perry
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·John Concato
Feb 2, 2006·Expert Opinion on Pharmacotherapy·Philip Home, Peter Kurtzhals
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Louis MonnierClaude Colette
Jul 18, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·K KølendorfS R Heller
Nov 15, 2006·The Diabetes Educator·Catherine Carver
Jan 18, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·K J RobertsonJ Ludvigsson
Mar 9, 2007·Diabetes Research and Clinical Practice·Nish Chaturvedi
Jul 7, 2007·Eating and Weight Disorders : EWD·S Tierney
Aug 2, 2007·Diabetes/metabolism Research and Reviews·J H DevriesT R Pieber
Nov 27, 2007·Clinical Therapeutics·Robert J LigthelmPaul Valensi
Aug 8, 2008·Primary Care Diabetes·Robert Ligthelm, Jaime Davidson
Nov 27, 2008·Diabetes·Philip E Cryer

❮ Previous
Next ❯

Citations

May 11, 2012·Medicina clínica·Jorge Manzarbeitia Arambarri, Leocadio Rodríguez Mañas
Jan 18, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·V V ShenoyH D McIntyre
Oct 31, 2017·Current Diabetes Reports·Ulrik Pedersen-Bjergaard, Birger Thorsteinsson
Jul 8, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Grace LedetTarun K Mandal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.